A new combination treatment for multiple myeloma that has stopped responding to prior drugs

Plain-English translation of NCT06158412 on ClinicalTrials.gov ↗ · Source last updated February 2025 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing all-trans retinoic acid (ATRA) combined with a three-drug regimen called KPD in patients with multiple myeloma that has relapsed (come back) or become refractory (stopped responding to prior treatment). The study will measure how well this medication combination works and what side effects patients experience. Researchers hope this new approach may help people whose myeloma is no longer controlled by standard treatments.

Multiple myeloma is a cancer of plasma cells in the bone marrow, and many patients eventually develop disease that either returns after treatment or stops responding to their current medications. This trial exists because doctors need better options for these patients, and early research suggests this medication combination may offer hope.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with multiple myeloma that has either relapsed (come back after initial treatment) or become refractory (stopped responding to treatment)
you have measurable disease detectable in blood or urine tests
you are in overall good enough health to tolerate treatment (ECOG score of 0, 1, or 2)
you have a life expectancy of at least 3 months
you are able to read, understand, and sign the informed consent form

You likely don't qualify if…

you are currently enrolled in or planning to enroll in another clinical trial
you received other myeloma treatments within 2 weeks before starting this study
you received a stem cell transplant within the past year and are still taking immunosuppressive medications
you have very low platelet or white blood cell counts (bone marrow that is not working well)
you have serious lung disease such as severe COPD or uncontrolled asthma

What participation looks like

You would receive the new medication combination (all-trans retinoic acid plus KPD regimen) over multiple treatment cycles. You would attend regular clinic visits for examinations, blood tests, and imaging scans to monitor how well the treatment is working and to check for side effects. The study will follow your response to treatment, overall survival, and how long the disease remains under control.

AI-generated summary from trial data · Jul 12, 2026 · Not medical advice

Trial locations(1 site)

China

Bing Xu, Xiamen, Fujian